Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    0.60 (0.12%)
Bid:
498.00
Ask:
500.50
Spread: 2.50 (0.502%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Norwegian feasibility study

26 Jun 2025 07:00

RNS Number : 5290O
Chemring Group PLC
26 June 2025
 

FOR IMMEDIATE RELEASE 26 JUNE 2025

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

NORWEGIAN FEASIBILITY STUDY MOVES TO SECOND STAGE

 

Chemring's 2025 interim results announcement, published on 3 June, provided an update on the joint feasibility study between the Norwegian Government and Chemring Nobel, Chemring's Norwegian subsidiary. This study, which commenced in October 2024, was initiated to assess the feasibility of an additional new production facility to significantly increase the production of military explosives, which are crucial to multiple NATO missile and munitions systems.

 

The first phase of this co-funded feasibility study investigated the geographic location, infrastructure requirements and environmental considerations of building a new production facility.

 

Chemring is pleased to announce that the Norwegian Government has confirmed that the study will now progress to its second phase. This concept selection phase will determine the size of the facility, along with the commercial arrangements, and is expected to be finalised next year.

 

Michael Ord, Chief Executive of Chemring, commented:

 

"We are delighted that the Norwegian Government has confirmed that this important study will continue to the next phase. This decision is a further indicator of the critical need to rapidly increase capacity across the European defence industrial base.

"This decision is further evidence of Chemring delivering its strategy of delivering growth through a combination of organic investment and bolt-on acquisitions in high-priority defence and national security markets."

ENDS

 

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Group 07584 142665

Ollie Hoare 07817 458804

 

 

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE250 global business that specialises in the manufacture of high technology products and the provision of services to the defence, aerospace and security markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREQLBLEQLLBBB
Date   Source Headline
2nd Dec 20247:00 amRNSTotal Voting Rights
14th Nov 20247:19 amRNSDirector Declaration
6th Nov 20247:15 amRNSDirector Declaration
4th Nov 20247:00 amRNS£278m Contract Wins
1st Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20247:00 amRNSTransaction in Own Shares
17th Oct 20247:00 amRNSTrading Update
14th Oct 202412:29 pmRNSHolding(s) in Company
1st Oct 20247:00 amRNSTotal Voting Rights
2nd Sep 20247:00 amRNSTotal Voting Rights
16th Aug 202410:10 amRNSAdditional Listing
5th Aug 202410:03 amRNSDirector/PDMR Shareholding
1st Aug 20247:00 amRNSTotal Voting Rights
18th Jul 20242:34 pmRNSDirector Declaration
1st Jul 20247:00 amRNSTotal Voting Rights
24th Jun 20247:00 amRNSAppointment of Chairman-designate
19th Jun 20247:00 amRNSBlock listing update
18th Jun 20247:00 amRNSBlock listing Interim Review
10th Jun 20247:00 amRNSContract Award
4th Jun 20247:00 amRNSHalf-year Report
3rd Jun 20247:00 amRNSTotal Voting Rights
1st May 202411:29 amRNSTotal Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:13 amRNSTotal Voting Rights
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSFunding Awards
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 202412:45 pmRNSResult of AGM
23rd Feb 20247:00 amRNSAGM Update
16th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.